Childhood Cancer Predisposition Study (CCPS)
The Childhood Cancer Predisposition Study (CCPS) is a multi-center, longitudinal, observational study that will collect clinical and biological data and specimens from children with a cancer predisposition syndromes (CPS) and their relatives. The central hypothesis is that studying individuals at high risk for childhoo
| Condition(s) | Pediatric Cancer |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The Childhood Cancer Predisposition Study (CCPS) is a multi-center, longitudinal, observational study that will collect clinical and biological data and specimens from children with a cancer predisposition syndromes (CPS) and their relatives. The central hypothesis is that studying individuals at high risk for childhood cancer creates a unique opportunity for improving the understanding of carcinogenesis, tumor surveillance, early detection, and cancer prevention, which will collectively contribute to improving care and outcomes for pediatric patients with cancer and those with cancer predisposition syndromes (CPS). |
| Who can participate | Inclusion Criteria: Primary Subjects must meet all of the below criteria to be eligible for enrollment: 1. Be less than 21 years of age at the time of enrollment 2. Have a diagnosis of a specific CPS, whether they have had cancer or not * Based on clinical laboratory testing demonstrating a Pathogenic or Likely Pathogenic germline variant and/or * Based on well-established clinical diagnostic criteria and/or * Based on high clinical suspicion of a specific CPS with clinical laboratory testing demonstrating a variant of uncertain significance (VUS) Affected Parents must meet all of the following criteria to be eligible for enrollment: 1. Be the biologic parent of a Primary Subject and 2. Carry a diagnosis (or obligate diagnosis) of the familial CPS Adult Affected Siblings must meet all of t |
| Sex | All |
| Lead sponsor | Emory University |
| Locations | Atlanta, Georgia, United States; Boston, Massachusetts, United States; Philadelphia, Pennsylvania, United States; Memphis, Tennessee, United States; Houston, Texas, United States; Salt Lake City, Utah, United States (+1 more sites) |
| Start date | 2021-04-22 |
| NCT ID | NCT04511806 |
| Official listing | https://clinicaltrials.gov/study/NCT04511806 |